← SynDRA
GUSACITINIB
SynDRA canonical compound SYN0039977 — structure-anchored drug synonym record
| Clinical phase | Phase 2 |
|---|
| Primary target(s) | CLDN23 | IL13 | IL36G | JAK1 | SYK |
|---|
| Mechanism of action | jak inhibitor |
|---|
| Indication | dermatitis |
|---|
| Disease area | dermatology |
|---|
All known targets
- SYK
- JAK1
- JAK2
- CLDN23
- IL13
- IL36G
- JAK3
- TYK2
Mechanisms of action (all sources)
- JAK3 INHIBITOR
- Janus Kinase (JAK) inhibitor
- JAK1 INHIBITOR
- JAK2 INHIBITOR
- TYK2 INHIBITOR
- SYK INHIBITOR
- Tyrosine-protein kinase SYK inhibitor
- JAK inhibitor
Cross-references
Synonyms
- ASN-002
- ASN002
- EN-3351
- EN3351
- POAZPIKWEFFCBP-UHFFFAOYSA-N
- GTPL10000
- 2-[1-(4-{[4-(4-hydroxypiperazin-1-yl)phenyl]amino}-5-oxo-5H,6H-pyrimido[4,5-d]pyridazin-2-yl)piperidin-4-yl]acetonitrile
- gusacitinibum
- RefChem:783278
- Gusacitinib [INN]
- Gusacitinib [USAN]
- Gusacitinib [USAN:INN]
- UNII-4801QYW816
- WHO 10976
- Gusacitinib (USAN/INN)
- Gusacitinib (ASN-002)?
- GUSACITINIB [WHO-DD]
- orb1308634
- SCHEMBL14717111
- SCHEMBL29467492
- AHC38160
- EX-A2668
- BDBM50595921
- MFCD31692335
- NSC818003
- AKOS040741172
- EBC-517167
- NSC-818003
- NCGC00842561-02
- AC-38217
- MS-28452
- DB-133043
- example 189 [WO2013028818A1]
- HY-103018
- CS-0023113
- D11676
- F78024
- G823720
Look up GUSACITINIB in the interactive SynDRA portal →